Live feed07:00:00·11dPRReleasevia QuantisnowKymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual MeetingByQuantisnow·Wall Street's wire, on your screen.KYMR· Kymera Therapeutics Inc.Health Care
